文献速递浆细胞疾病

美法仑氟芬联合地塞米松治疗复发难治多发性骨髓瘤的1-2期研究

Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
PubMed 文献 · Lancet Haematol · 2020-03-23

这项多中心、开放标签1-2期研究评估了美法仑氟芬联合地塞米松在复发难治多发性骨髓瘤患者中的最大耐受剂量、安全性和疗效。1期确定最大耐受剂量为美法仑氟芬40mg联合地塞米松;2期联合治疗组总缓解率为31%(95%CI 18-47),临床获益率为49%(95%CI 34-64)。常见3-4级不良事件为血小板减少和中性粒细胞减少。

要点

  • 美法仑氟芬联合地塞米松的最大耐受剂量为40mg。
  • 2期联合治疗组总缓解率31%,临床获益率49%。
  • 常见3-4级不良事件为血小板减少和中性粒细胞减少。

核心结论

  • 美法仑氟芬在复发难治多发性骨髓瘤患者中具有活性且多数患者可耐受。
  • 结果支持进一步开展美法仑氟芬联合地塞米松或三药联合方案的临床研究。

研究设计与样本

  • 多中心、国际、开放标签、剂量确认和剂量扩展的1-2期研究,在美国和欧洲7个中心进行。
  • 纳入年龄≥18岁、复发难治多发性骨髓瘤、既往接受≥2线治疗(包括来那度胺和硼替佐米)、对末线治疗难治、ECOG体能状态≤2的患者。
  • 1期23例,2期58例(包括6例来自1期在最大耐受剂量治疗的患者);2期联合组45例,单药组13例。

主要发现

  • 1期确定最大耐受剂量为美法仑氟芬40mg联合地塞米松;55mg剂量组6例中4例出现4级中性粒细胞减少,其中3例同时出现4级血小板减少,超出最大耐受剂量。
  • 2期联合治疗组全治疗人群总缓解率31%(14/45,95%CI 18-47),临床获益率49%(22/45,95%CI 34-64);疗效可评估人群分别为41%(14/34,95%CI 25-59)和65%(22/34,95%CI 47-80)。
  • 2期联合组最常见3-4级不良事件为血小板减少(28例[62%])和中性粒细胞减少(26例[58%]);17例(38%)报告24例严重不良事件,最常见为肺炎(5例[11%])。
  • 2期单药组最常见3-4级不良事件为中性粒细胞减少(9例[69%])和血小板减少(8例[62%]);9例发生严重不良事件,最常见为血小板减少(2例[15%])。

关键数值与推荐

  • 最大耐受剂量:美法仑氟芬40mg联合地塞米松。
  • 2期联合组全治疗人群总缓解率31%(95%CI 18-47),临床获益率49%(95%CI 34-64)。
  • 2期联合组疗效可评估人群总缓解率41%(95%CI 25-59),临床获益率65%(95%CI 47-80)。

临床怎么用

  • 美法仑氟芬40mg联合地塞米松可作为复发难治多发性骨髓瘤的候选方案,需关注血液学毒性。
  • 治疗期间应监测血小板和中性粒细胞计数,并警惕感染事件。

局限性

  • 样本量较小,2期联合组仅45例,单药组仅13例。
  • 单药组因中期数据提示联合组活性更优而提前关闭。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multiple myeloma is an incurable haematological malignancy, representing over 10% of haematological cancers in the USA. We did a phase 1-2 study of melflufen and dexamethasone in patients with relapsed and refractory multiple myeloma to determine the maximum tolerated dose of melflufen and to investigate its safety and efficacy. METHODS: We did a multicentre, international, dose-confirmation and dose-expansion, open-label, phase 1-2 study in seven centres in the USA and Europe. Eligible patients were aged 18 years or older, had relapsed and refractory multiple myeloma, had received two or more previous lines of therapy (including lenalidomide and bortezomib), were refractory to their last line of therapy, and had an Eastern Cooperative Oncology Group performance status of 2 or less. In phase 1, patients received an intravenous infusion of melflufen at 15 mg, 25 mg, 40 mg, or 55 mg for 30 min on day 1 in 21-day cycles plus oral dexamethasone 40 mg weekly and did not receive melflufen as a single agent. Melflufen was also tested in a single-agent cohort late in phase 2 in a small number of patients at the maximum tolerated dose identified in phase 1. In phase 2, patients were enrolled at the maximum tolerated dose in the melflufen plus dexamethasone in the combination cohort.. The phase 1 primary objective was to determine the maximum tolerated dose. The phase 2 primary objective was to evaluate overall response rate and clinical benefit rate. This primary analysis was done per protocol, in the all-treated and efficacy-evaluable population (defined as patients who received at least two doses of melflufen and who had a response assessment after baseline). The single-agent melflufen cohort was closed on October 6, 2016, as per the recommendation by the data safety monitoring committee on the basis of interim data suggesting greater activity in the melflufen plus dexamethasone cohort. The study is completed but survival follow-up is ongoing. This study is registered with ClinicalTrials.gov, NCT01897714. FINDINGS: Patients were enrolled between July 4, 2013, and Dec 31, 2016: 23 patients in phase 1 and 58 in phase 2, including six patients from phase 1 treated at the maximum tolerated dose of melflufen 40 mg plus weekly dexamethasone. In phase 2, 45 patients were given a combination of melflufen plus dexamethasone and 13 patients were given single-agent melflufen. In phase 1, the established maximum tolerated dose was 40 mg of melflufen in combination with dexamethasone. No dose-limiting toxicities were observed in the first three dose cohorts (15 mg, 25 mg, and 40 mg). The highest dose cohort tested (55 mg) exceeded the maximum tolerated dose because four of six patients experienced grade 4 neutropenia with grade 4 thrombocytopenia also occurring in three of these patients; therefore, the planned highest dose of 70 mg was not tested. In phase 2, patients treated with combination therapy achieved an overall response rate of 31% (14 of 45 patients; 95% CI 18-47) and clinical benefit rate of 49% (22 of 45; 34-64) in the all-treated population, and 41% (14 of 34; 25-59) and 65% (22 of 34; 47-80) in the efficacy-evaluable population. In the phase 2 single-agent cohort, the overall response rate was 8% (one of 13 patients; 0·2-36·0) and the clinical benefit rate was 23% (three of 13; 5-54). Among the 45 patients given melflufen plus dexamethasone during phase 2, the most common grade 3-4 adverse events were clinically manageable thrombocytopenia (28 [62%] patients) and neutropenia (26 [58%]), and non-haematological toxicity was infrequent. 24 serious adverse events were reported in 17 (38%) of 45 patients, most commonly pneumonia (five [11%]). The most common grade 3-4 adverse events that occurred in the phase 2 single-agent cohort of 13 patients were neutropenia (nine [69%]) and thrombocytopenia (eight [62%]). Nine patients experienced serious adverse events in the single-agent cohort, most commonly thrombocytopenia (two [15%]). There were three deaths from adverse events within 30 days of treatment that were possibly related to treatment: one in the 25 mg cohort in phase 1 (due to bacteraemia) and two in the phase 2 combination cohort (one due to neutropenic sepsis and one due to Escherichia coli sepsis), each in the setting of progressive disease. INTERPRETATION: These data show that melflufen is active in patients with relapsed and refractory multiple myeloma and tolerable in most patients. These results show the feasibility of this regimen and support the initiation of additional clinical studies of melflufen in multiple myeloma, both in combination with dexamethasone as well as in triplet regimens with additional classes of drugs. FUNDING: Oncopeptides AB.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Richardson PG, Bringhen S, Voorhees P, et al. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. Lancet Haematol. 2020. PMID: 32213344. doi:10.1016/S2352-3026(20)30044-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。